bioMérieux 将来の成長

Future 基準チェック /26

bioMérieux利益と収益がそれぞれ年間13.6%と7.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に12.8% 13.5%なると予測されています。

主要情報

13.6%

収益成長率

13.5%

EPS成長率

Medical Equipment 収益成長	14.2%
収益成長率	7.3%
将来の株主資本利益率	12.8%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:EYWN - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,562	607	416	906	12
12/31/2025	4,233	536	383	839	13
12/31/2024	3,948	474	420	776	14
6/30/2024	3,807	411	156	495	N/A
3/31/2024	3,741	384	132	470	N/A
12/31/2023	3,675	358	107	445	N/A
9/30/2023	3,688	372	140	459	N/A
6/30/2023	3,701	386	172	472	N/A
3/31/2023	3,645	419	180	474	N/A
12/31/2022	3,589	452	188	475	N/A
9/30/2022	3,525	502	297	583	N/A
6/30/2022	3,460	552	406	690	N/A
3/31/2022	3,418	577	470	757	N/A
12/31/2021	3,376	601	535	825	N/A
9/30/2021	3,296	555	424	716	N/A
6/30/2021	3,216	509	314	608	N/A
3/31/2021	3,167	457	310	595	N/A
12/31/2020	3,118	404	305	583	N/A
9/30/2020	2,997	355	261	538	N/A
6/30/2020	2,876	305	217	493	N/A
3/31/2020	2,775	289	176	451	N/A
12/31/2019	2,675	273	135	408	N/A
9/30/2019	2,601	268	160	419	N/A
6/30/2019	2,527	263	185	431	N/A
3/31/2019	2,474	260	179	415	N/A
12/31/2018	2,421	257	173	400	N/A
9/30/2018	2,372	264	162	370	N/A
6/30/2018	2,323	271	150	340	N/A
3/31/2018	2,306	255	N/A	341	N/A
12/31/2017	2,288	238	N/A	341	N/A
9/30/2017	2,262	216	N/A	340	N/A
6/30/2017	2,237	195	N/A	339	N/A
3/31/2017	2,170	187	N/A	337	N/A
12/31/2016	2,103	179	N/A	336	N/A
9/30/2016	2,068	158	N/A	339	N/A
6/30/2016	2,032	137	N/A	342	N/A
3/31/2016	1,998	124	N/A	326	N/A
12/31/2015	1,965	111	N/A	310	N/A
9/30/2015	1,908	127	N/A	N/A	N/A
6/30/2015	1,851	144	N/A	301	N/A
3/31/2015	1,775	140	N/A	300	N/A
12/31/2014	1,698	135	N/A	298	N/A
9/30/2014	1,656	135	N/A	N/A	N/A
6/30/2014	1,614	135	N/A	246	N/A
3/31/2014	1,601	150	N/A	243	N/A
12/31/2013	1,588	164	N/A	241	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EYWNの予測収益成長率 (年間13.6% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: EYWNの収益 ( 13.6% ) German市場 ( 21.1% ) よりも低い成長が予測されています。

高成長収益: EYWNの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: EYWNの収益 ( 7.3% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: EYWNの収益 ( 7.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EYWNの自己資本利益率は、3年後には低くなると予測されています ( 12.8 %)。

bioMérieux 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

bioMérieux S.A. Issues No Annual Guidance for 2020

Recent updates

First half 2024 earnings released: EPS: €1.83 (vs €1.37 in 1H 2023)

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

New minor risk - Earnings quality

Dividend of €0.85 announced

Full year 2023 earnings released: EPS: €3.03 (vs €3.84 in FY 2022)

bioMérieux S.A., Annual General Meeting, May 23, 2024

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Upcoming dividend of €0.85 per share at 0.9% yield

Full year 2022 earnings released: EPS: €3.84 (vs €5.08 in FY 2021)

bioMérieux Introduces GENE-UP ENVIROPRO

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Upcoming dividend of €0.85 per share

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Upcoming dividend of €0.62 per share

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Revenue misses expectations

New 90-day low: €110

bioMérieux S.A., Annual General Meeting, May 20, 2021

bioMérieux S.A. Announces the Expansion of the Ce Marking of Its Molecular Biology Argene® Sars-Cov-2 Diagnostic Test to Include Saliva Specimens

bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions with Data Science, Sequencing and Predictive Modeling

bioMérieux S.A. Issues No Annual Guidance for 2020

New 90-day high - €138

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘